Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
RBM rev. bras. med ; 72(7)jul. 2015.
Article in Portuguese | LILACS | ID: lil-771200

ABSTRACT

Chronic Venous Disorder (CVD) is a term used to represent all abnormal clinical changes that result from venous disease of the lower extremities, and that have a chronic pattern. This disease has a documented socioeconomic impact, involving a significant part of the western populations, and consuming 2-3% or more of societies? health budgets. This review of the literature focuses on diosmin, a benzopyrone phlebotonic, specifically mechanisms of action as well as preclinical and clinical evidence.


Subject(s)
Humans , Diosmin , Venous Insufficiency
2.
GED gastroenterol. endosc. dig ; 31(3): 107-115, jul.-set. 2012. ilus
Article in Portuguese | LILACS | ID: lil-702836

ABSTRACT

A Colecistite Alitiásica Aguda (CAA) é uma inflamação da vesícula biliar na ausência de colelitíase. É uma forma pouco frequente de colecistite, representando cerca de 10% de todos os casos, sendo tradicionalmente descrita em pacientes graves, submetidos a grandes procedimentos cirúrgicos, queimados, sépticos, politraumatizados ou em nutrição parenteral total por tempo prolongado. Existem relatos na literatura da sua associação também com o diabetes mellitus, insuficiência cardíaca, síndrome da imunodeficiência adquirida, dentre outras patologias. Doenças autoimunes como poliarterite nodosa e Lúpus Eritematoso Sistêmico (LES) também podem se manifestar através da CAA, causada por uma lesão isquêmica na vesícula biliar. Nosso objetivo é relatar um caso clínico de Colecistite Alitiásica Aguda numa paciente sem fator de risco que, durante a evolução, apresenta quadro de rash cutâneo facial, com Fator Antinuclear (FAN) positivo, porém sem critérios diagnósticos para LES segundo os protocolos e que, após início da corticoterapia, apresentou remissão total dos sintomas.


The Acute Cholecystitis Alitiasica (CAA) is an inflammation gallbladder in the absence of cholelithiasis. It is a Uncommonly of cholecystitis, representing about 10% of all cases, traditionally described in critically ill patients undergoing to major surgical procedures, burns, sepsis, multiple trauma or parenteral nutrition total time for prolongado. There are reports in literature also its association with diabetes mellitus, heart failure, immunodeficiency syndrome acquired, among other patologias. Diseases as autoimmune lupus erythematosus and polyarteritis nodosa (SLE) may also manifest by CAA, caused by an ischemic lesion in gall biliar. Our goal is to report a case Acute cholecystitis in a patient without Alitiásica factor risk that during evolution, presents frame facial rash with antinuclear antibodies (ANA) antibody positive, but no diagnostic criteria for SLE according to protocols and that after the start of steroid therapy, showed total remission of symptoms.


Subject(s)
Humans , Female , Adult , Carcinoma, Squamous Cell , Acalculous Cholecystitis , Autoimmune Diseases , Cholelithiasis , Cholecystitis , Cholecystitis, Acute , Gallbladder
3.
Rev. Soc. Bras. Clín. Méd ; 8(4)jul.-ago. 2010.
Article in Portuguese | LILACS | ID: lil-555451

ABSTRACT

JUSTIFICATIVA E OBJETIVOS: A tosse persistente representa uma condição comum e causa frequente de procura por atendimento médico, podendo alterar a rotina diária do paciente afetado. O objetivo deste estudo foi avaliar a resposta clínica e laboratorial à terapia de tosse persistente, utilizando uma combinação de eucaliptol, gomenol, guaifenesina, cansilato de sódio e cloridrato de lidocaína.MÉTODO: Foram obtidos dados referentes a 60 pacientes atendidos no Serviço de Pneumologia do Hospital das Clínicas de Teresópolis Constantino Otaviano, incluindo informações demográficas, resultados de exames físicos, laboratoriais e de espirometria, avaliações do médico e do paciente, bem como uma avaliação através do Cough-specific Quality of Life Questionnaire (CQLQ) que foram analisadas antes, durante e após sete dias de terapia. RESULTADOS: Não houve alterações clinicamente significativas nos exames físicos. Os exames laboratoriais e testes de espirometria permaneceram dentro das respectivas faixas de normalidade e nenhuma diferença significativa nos valores entre as avaliações foi observada. Vinte e nove eventos adversos foram registrados em 22 pacientes, todos com gravidade leve a moderada. As pontuações das avaliações de condição geral do médico e do paciente melhoraram significativamente na Avaliação 3 em relação à Avaliação 1 (Qui-quadrado = 121,1; GL= 16; p < 0,0001, e Qui-quadrado = 61,86; GL = 16; p < 0,0001, respectivamente). As pontuações no CQLQ da Avaliação 3 melhoraram de forma significativa em relação às da Avaliação 1 (t = 6,746; GL = 58; p < 0,0001), indicando melhora substancial na qualidade de vida.CONCLUSÃO: Com base nos resultados obtidos, concluiu-se que a combinação de eucaliptol, gomenol, guaifenesina, cansilato de sódio e cloridrato de lidocaína foi segura e eficaz em pacientes com processos pulmonares produtivos acompanhados de tosse, com impacto positivo na qualidade de vida dos pacientes tratados.


BACKGROUND AND OBJECTIVES: Persistent cough represents a common ailment for which medical attention is often sought, and may cause significant disruption of the affected patient's routine. The objective of this study was to evaluate clinical and laboratory response to persistent cough therapy using a combination of eucalyptol, gomenol, guaifenesin, sodium camsilate, and lidocaine hydrochloride. METHOD: We collected data from 60 patients attended at the Pneumology Service of the Hospital de Clínicas de Teresópolis Constantino Otaviano, including demographic information, physical exams, laboratory, and spirometry exam results, physician and patient evaluations, and a quality-of-life assessment (CQLQ) which were analyzed before, during, and after seven days of therapy. RESULTS: There were no clinically significant changes regarding physical exams. Laboratory exams and spirometry tests remained within the respective normal ranges, and no statistically significant difference in values among study assessments was observed. Twenty-nine adverse events were recorded among 22 patients, all of which were mild to moderate in severity. The scores of the physician and patient evaluation of overall condition improved significantly in Assessment 3 in relation to Assessment 1 (Chi-square = 61.86; Degree of Freedom = 16; p < 0.0001 and Chi-square = 121.1; DF= 16; p < 0.0001, respectively). CQLQ total scores from Assessment 3 improved significantly in relation to those of Assessment 1 (t = 6.746; DF = 58; p < 0.0001), indicating a substantial improvement in quality-of-life. CONCLUSION: Based on the results of this analysis, we conclude that the combination of eucalyptol, gomenol, guaifenesin, sodium camsilate, and lidocaine hydrochloride, was safe and effective in patients with productive pulmonary processes accompanied by cough, positively impacting quality-of-life of the treated patients.


Subject(s)
Humans , Male , Female , Middle Aged , Cough , Quality of Life
5.
RBM rev. bras. med ; 66(11)nov. 2009.
Article in Portuguese | LILACS | ID: lil-536530

ABSTRACT

The use of a combination of uridine triphosphate (UTP), cytidine monophosphate (CMP), and hydroxocobalamin was evaluated in a double-blind, randomized study in the treatment of neuralgia due to degenerative orthopedic alterations with neural compression. Following informed consent, 80 patients were randomized to a 30 day treatment period. The subjects received a thrice-daily oral treatment regimen of either the combination treatment (Group A: total daily dose of 9mg UTP, 15mg CMP, 6 mg hydroxocobalamin) or vitamin B12 alone (Group B: total daily dose of 6 mg hydroxocobalamin). Efficacy measures evaluated global patient condition from the perspective of the subject and the investigating physician pain ? measured by a visual-analog scale and functionality, using a patient-response questionnaire. The safety evaluation took into account physical evaluations and laboratory tests performed at each visit to the study center as well as the incidence and severity of adverse events. At the end of the 30-day treatment period, there were reductions in the pain scale scores in both groups, however there was a significantly larger reduction in the scores of the Group A patients. The Patient Global Evaluation scores improved in both groups but showed greater improvement in Group A, while the Physician Global Evaluation improved significantly only in Group A. A similar finding was observed in the scores of the Patient Functionality Questionnaire. Based on the findings of this clinical trial, we conclude that the combination of UTP, CMP, and vitamin B12 has a positive effect on pain and functionality improvement in the treatment of degenerative orthopedic alterations with neural compression, in the study population evaluated.


Subject(s)
Adult , Middle Aged , Cytidine/therapeutic use , Uridine/therapeutic use , /therapeutic use , Neuralgia/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL